Welcome to our dedicated page for UNITEDHEALTH GROUP SEC filings (Ticker: UNH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on UNITEDHEALTH GROUP's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into UNITEDHEALTH GROUP's regulatory disclosures and financial reporting.
UnitedHealth Group reported second quarter 2026 revenue of $112.0 billion and earnings from operations of $8.0 billion, producing a net margin of 4.9%. Diluted EPS was $6.04 and adjusted EPS $6.38. The medical cost ratio was 86.7%, compared with 89.4% a year earlier, while the operating cost ratio was 12.7%. Cash flows from operations were $11.1 billion (1.9x net income), and the debt‑to‑capital ratio stood at 41.2% as of June 30, 2026. UnitedHealthcare generated $86.0 billion of revenue and $3.9 billion of operating earnings, serving 48.5 million people, while Optum delivered $65.7 billion of revenue and $4.0 billion of operating earnings with margin expansion.
The company raised its full‑year 2026 diluted EPS outlook to $18.45–$18.95 and adjusted EPS to $19.50–$20.00, with operating cash flows projected at about $24 billion and at least $5.0 billion of share repurchases. Management highlighted ongoing reforms including a $1 billion commitment to the United Health Foundation, plans to eliminate and rebate 2026 profits from individual Affordable Care Act coverage to about 1 million members, substantial reductions in prior approval requirements, and a transparent, fee‑based pharmacy care model with a commitment to 100% pass‑through of manufacturer rebates by 2028.
Noseworthy John H reported acquisition or exercise transactions in this Form 4 filing.
UNITEDHEALTH GROUP INC director John H. Noseworthy received a grant of 206 shares of common stock in the form of deferred stock units as regular quarterly compensation for board service. These units are immediately vested but must be held until he completes his service on the Board, bringing his direct holdings to 7,616 shares.
MONTGOMERY RICE VALERIE MD reported acquisition or exercise transactions in this Form 4 filing.
UNITEDHEALTH GROUP INC director Valerie Montgomery Rice received a grant of 220 shares of Common Stock in the form of deferred stock units as regular quarterly compensation for Board service. These units are immediately vested and increase her direct holdings to 7,876 shares following the transaction.
The deferred stock units must be retained until she completes her service on the Board, aligning her compensation with longer-term director tenure rather than short-term trading.
MCNABB FREDERICK WILLIAM III reported acquisition or exercise transactions in this Form 4 filing.
UNITEDHEALTH GROUP INC director Frederick William McNabb III received an award of 250 deferred stock units of Common Stock as regular quarterly compensation for board service. These units are immediately vested but must be held until he completes his service on the Board. Following this award, he directly holds 15,462 shares/units.
UnitedHealth Group director Scott Gottlieb reported a routine equity grant of 210 deferred stock units of common stock. The units were granted as regular quarterly compensation for his service on the board and carry no cash exercise price. After this award, he directly holds 659 deferred stock units. According to the disclosure, these units vest immediately but must be retained until he completes his service on the board, so they function as long-term, stock-based director compensation rather than a short-term trading position.
Gil Kristen reported acquisition or exercise transactions in this Form 4 filing.
UnitedHealth Group director Kristen Gil received an award of 206 shares of common stock in the form of deferred stock units. The units are granted as regular quarterly compensation for board service, are immediately vested, and must be held until Gil’s service on the Board ends. After this grant, Gil directly holds 2,617 shares, with an additional 3,800 shares held indirectly through a trust.
GARCIA PAUL R reported acquisition or exercise transactions in this Form 4 filing.
UnitedHealth Group director Paul R. Garcia reported routine equity awards and updated his indirect holdings. On July 1, 2026, he received 88 shares of common stock and 132 deferred stock units as regular quarterly compensation for board service, both at a stated price of $0.00 per share.
After these awards, Garcia directly holds 3,906 shares following the 88-share grant and 3,818 shares following the 132-unit grant, and also reports indirect holdings of 55 shares in Trust 3, 45 shares in Trust 2, and 2,146 shares in a revocable trust. The deferred stock units are immediately vested but must be retained until he completes board service.
FLYNN TIMOTHY PATRICK reported acquisition or exercise transactions in this Form 4 filing.
UNITEDHEALTH GROUP INC director Timothy Patrick Flynn received an equity award of 225 shares of common stock-equivalent units as compensation. These deferred stock units were granted at a price of $0.00 per unit, are immediately vested, and must be held until he completes his Board service.
After this grant, Flynn directly holds 10,875 shares of UnitedHealth Group common stock. Separately, a trust associated with him indirectly holds 6,033 shares. The filing does not show any open‑market buying or selling; this is a routine compensation-related award rather than a discretionary trade.
Baker Charles D. reported acquisition or exercise transactions in this Form 4 filing.
UNITEDHEALTH GROUP INC director Charles D. Baker received an equity award of 220 deferred stock units as regular quarterly compensation for board service. These units are immediately vested but must be held until he completes his service on the Board. Following this grant, he directly holds 2,396 common shares-equivalent.
UNITEDHEALTH GROUP INC executive Erin McSweeney, EVP & Chief People Officer, acquired 48.23 shares of common stock on June 23, 2026 as a grant of dividend equivalents on outstanding restricted stock units, at a stated price of $0.00 per share. After this compensation-related award, her direct holdings increased to 15,601.153 shares of common stock. The dividend-equivalent shares are subject to the same vesting conditions as the underlying restricted stock units and are forfeited if those units do not vest.